GENE ONLINE|News &
Opinion
Blog

Licensing
LG Chem Lands Innovent As China Partner For Gout Candidate
2022-12-15
Clovis Offloads Cancer Candidate to Novartis, Day After Declaring Bankruptcy
2022-12-13
Astellas Invests $50 Million In Taysha, Licenses Two CNS Gene Therapies
2022-10-25
Kite to Use Refuge’s Gene Expression Platform for New CAR-T Therapies
2022-10-21
Pfizer Opts In On Neurological Target In Voyager Deal, Leaving $290 Million In Milestones
2022-10-05
Novo Nordisk Places $700 Million Bet on Ventus’ NLRP3 Inhibitor Program
2022-09-30
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
AstraZeneca Blocks Ionis’ Hypercholesterolemia Treatment from Moving into a Phase 3 Study
2022-09-23
Gilead Forking Over $280 million to Everest to Regain Rights to Breast Cancer Treatment
2022-08-16
GSK Puts Up $100 Million for Mersana’s HER2-Targeting ADC Candidate
2022-08-09
Sanofi Invests in Innovent to Gain Stronger Foothold in China
2022-08-05
Sosei Heptares and Abbvie Partner in Potential $1.2 Billion Neurological Disease Deal
2022-08-02
Oncology Research Collaboration between Kelun-Biotech and MSD
2022-07-27
Takeda Throws $1 Million at F-star to Develop Bispecific Antibody For Novel Cancer Therapies
2022-07-21
Roche Receives Rights to Ionis’ Antisense Kidney Disease Drug for $55 Million
2022-07-12
1 2 3 4 7
LATEST
Ginkgo Bioworks and Pfizer Forge $331 Million Collaboration for RNA-Based Drug Discovery
2023-09-29
Johnson & Johnson Partners with Singapore to Boost Life Sciences Innovation
2023-09-28
Vietnam and South Korea Strengthen Cooperation in Multiple Sectors
2023-09-27
PeptiDream and Genentech Collaborate on Novel Peptide-Radioisotope Drug Conjugates
2023-09-27
AcuraStem and Takeda Collaborate on Innovative ALS Treatment
2023-09-27
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
2023-09-27
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
EVENT
2023-10-04
BioFuture 2023
New York city,USA
Scroll to Top